证券日报网讯 10月20日晚间，辽宁成大发布公告称，公司无逾期对外担保。 （文章来源：证券日报） ...

证券代码：600739 证券简称：辽宁成大 公告编号：2025-076 关于为控股子公司融资提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 保 | 被担保人名称 本次担保金额 | 10,000.00 | 辽宁成大国际贸易有限公司 万元 | | | --- | --- | --- | --- | --- | | 担 | | | | | | 对象 | 实际为其提供的担保余额（含本 次） | 58,460.50 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | 否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日公司及控股子公司 | 706,600.00 | | 已批准的对外担保总额（万元） | | | 已批准的对外担保总额占公司最 | 24.12% | | 近一期经审计净资产的 ...

Core Viewpoint - Liaoning Chengda's stock price decreased by 2.06% on October 16, 2023, with a current price of 12.39 CNY per share and a total market capitalization of 18.953 billion CNY [1] Financial Performance - For the first half of 2025, Liaoning Chengda reported revenue of 5.348 billion CNY, a year-on-year decrease of 0.83%, while net profit attributable to shareholders increased by 56.18% to 718 million CNY [1] - The company has cumulatively distributed dividends of 2.11 billion CNY since its A-share listing, with 411 million CNY distributed over the past three years [2] Stock Market Activity - As of October 16, 2023, the stock experienced a net outflow of 17.3381 million CNY from main funds, with significant selling pressure observed [1] - The stock has seen a year-to-date increase of 19.94%, with a slight decline of 0.48% over the last five trading days [1] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 5.14% to 66,000, while the average number of circulating shares per person increased by 5.42% to 23,173 shares [1] - Notable institutional holdings include Southern CSI 500 ETF, which increased its holdings by 1.9215 million shares, and Hong Kong Central Clearing Limited, which increased its holdings by 1.5646 million shares [2]

Market Overview - The biopharmaceutical sector experienced a decline of 1.28% on October 13, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Teabo Bio (688278) with a closing price of 83.89, up 2.91% [1] - ST Sihuan (000518) with a closing price of 2.42, up 2.11% [1] - Wanzhe Co. (000534) with a closing price of 15.88, up 1.99% [1] - Major decliners included: - Baipusais (301080) with a closing price of 57.65, down 6.11% [2] - Changchun High-tech (000661) with a closing price of 132.06, down 3.11% [2] - Tibet Pharmaceutical (600211) with a closing price of 47.50, down 2.84% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 432 million yuan from institutional investors, while retail investors contributed a net inflow of 246 million yuan [2] - The capital flow for specific stocks showed: - Changchun High-tech (000661) had a net outflow of 51.35 million yuan from institutional investors [3] - Baipusais (301080) experienced a net inflow of 8.11 million yuan from institutional investors [3] - SanSheng GuoJian (688336) had a net inflow of 9.14 million yuan from institutional investors [3]

券代码：600739 证券简称：辽宁成大 公告编号：2025-074 辽宁成大股份有限公司关于2024年度第三期短期融资券到期兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2022年5月31日，辽宁成大股份有限公司（以下简称"公司"）2021年年度股东大会审议通过了《关于注 册短期融资券发行额度的议案》，公司向中国银行间市场交易商协会申请注册金额不超过20亿元（含） 人民币的短期融资券发行额度。公司于2024年9月26日完成了2024年度第三期短期融资券的发行，金额 为人民币7亿元，期限为一年，票面利率为2.9%，票面价格100元/百元面值。 2024年度第三期短期融资券已于2025年9月27日到期，公司已完成该期短期融资券本息的兑付。 特此公告。 辽宁成大股份有限公司董事会 2025年9月30日 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600739 证券简称：辽宁成大 公告编号：2025-075 辽宁成大股份有限公司 2025年第三次临时股东会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 444 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 695,822,141 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 45.7081 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 本次会议由董事会提议召开，由董事长徐飚先生主持，以记名投票方式表决。 (一) 股东会召开的时间：2025 年 9 月 30 日 (二) 股东会召开的地点：公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 会议采用现场投票和网络投票相结合的方式进行。会议的召开、表决方式符合《公 司法》及《公司章程》的规 ...

辽宁恒信律师事务所 关于辽宁成大股份有限公司2025年第三次临时股东会的 法律意见书 致：辽宁成大股份有限公司 辽宁恒信律师事务所（以下简称"本所"）接受辽宁成大股份有限公司（以 下简称"公司"）的委托，指派张贞东律师、于璇聪律师（以下简称"本所律师"） 出席公司2025年第三次临时股东会（以下简称"本次股东会"），并对本次股东 会的合法性进行见证。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）等有关法律、法规和规范性文件以及《辽宁成大股份 有限公司章程》（以下简称"《公司章程》"），本所律师审查了公司提供的如 下文件： 辽宁恒信律师事务所 法律意见书 1. 公司现行的《公司章程》； 2. 公司于2025年8月29日召开的第十一届董事会第六次会议的《董事会决 议》； 3. 公司于2025年8月30日刊登于《中国证券报》《上海证券报》《证券时报》 《证券日报》与上海证券交易所网站（http://www.sse.com.cn）的《辽宁成大股 份有限公司第十一届董事会第六次会议决议公告》；公司于2 ...

2025 年 9 月 30 日 2022 年 5 月 31 日，辽宁成大股份有限公司（以下简称"公司"）2021 年年 度股东大会审议通过了《关于注册短期融资券发行额度的议案》，公司向中国银 行间市场交易商协会申请注册金额不超过 20 亿元（含）人民币的短期融资券发 行额度。公司于 2024 年 9 月 26 日完成了 2024 年度第三期短期融资券的发行， 金额为人民币 7 亿元，期限为一年，票面利率为 2.9%，票面价格 100 元/百元面 值。 2024 年度第三期短期融资券已于 2025 年 9 月 27 日到期，公司已完成该期 短期融资券本息的兑付。 特此公告。 辽宁成大股份有限公司 关于 2024 年度第三期短期融资券到期兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司董事会 证券代码：600739 证券简称：辽宁成大 公告编号：2025-074 ...

Market Overview - The biopharmaceutical sector increased by 0.78% on September 29, with Norseland leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Top Gainers in Biopharmaceutical Sector - Norseland (Code: 430047) closed at 24.80, up 6.57% with a trading volume of 68,400 shares and a transaction value of 169 million yuan [1] - Liaoning Chengda (Code: 600739) closed at 12.54, up 4.85% with a trading volume of 311,400 shares and a transaction value of 384 million yuan [1] - Rongchang Biotech (Code: 688331) closed at 110.00, up 4.76% with a trading volume of 83,500 shares and a transaction value of 900 million yuan [1] Top Losers in Biopharmaceutical Sector - Kanghua Biotech (Code: 300841) closed at 75.47, down 2.34% with a trading volume of 40,800 shares and a transaction value of 307 million yuan [2] - Baipusais (Code: 301080) closed at 58.51, down 2.32% with a trading volume of 20,000 shares and a transaction value of 117 million yuan [2] - Rili Pharmaceutical (Code: 603087) closed at 76.37, down 2.18% with a trading volume of 120,740 shares and a transaction value of 1.573 billion yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 154 million yuan from institutional investors, while retail investors saw a net inflow of 1.47 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2][3] Individual Stock Capital Flow - Liaoning Chengda saw a net outflow of 52.59 million yuan from institutional investors, while retail investors had a net outflow of 40.07 million yuan [3] - Kanghua Biotech had a net inflow of 26.12 million yuan from institutional investors, but a net outflow of 47.70 million yuan from retail investors [3] - Three Life National Health (Code: 688336) had a net inflow of 23.37 million yuan from institutional investors, with retail investors also experiencing a net outflow [3]

Core Points - The company has successfully issued a short-term financing bond with a total amount of 800 million RMB [1] - The registered amount for short-term financing bonds is 3 billion RMB, valid for two years [1] - The funds raised will primarily be used to repay interest-bearing debts [1] Summary by Sections - **Issuance Details** - The company issued 800 million RMB of short-term financing bonds on September 23, 2025 [1] - The funds were fully received on September 24, 2025 [1] - **Approval and Registration** - The issuance was approved during the company's second extraordinary general meeting on October 23, 2024 [1] - The China Interbank Market Dealers Association issued a registration acceptance notice for the bond [1] - **Underwriting** - Dalian Bank Co., Ltd. acted as the lead underwriter for the bond issuance [1]